(Q45422073)

14 December 2017

title

Sustained E2 antibody response correlates with reduced peak viremia after hepatitis C virus infection in the chimpanzee (English)

1 reference

14 December 2017

1 reference

1 reference

0 references

1 reference

3

1 reference

14 December 2017

13

Young Chul Sung

1 reference

14 December 2017

Jin-Won Youn

1

1 reference

14 December 2017

Su-Hyung Park

2

1 reference

14 December 2017

Francois-Loic Cosset

4

1 reference

14 December 2017

Se-Hwan Yang

5

1 reference

14 December 2017

Chang Geun Lee

6

1 reference

14 December 2017

Hyun-Tak Jin

7

1 reference

14 December 2017

Chang-Min Kim

8

1 reference

14 December 2017

Mohamed Tarek M Shata

9

1 reference

14 December 2017

Dong-Hun Lee

10

1 reference

14 December 2017

Wolfram Pfahler

11

1 reference

14 December 2017

Alfred M Prince

12

1 reference

14 December 2017

language of work or name

English

0 references

publication date

1 December 2005

1 reference

14 December 2017

1 reference

14 December 2017

volume

42

1 reference

14 December 2017

issue

6

1 reference

14 December 2017

page(s)

1429-1436

1 reference

Transition of antibody to hepatitis C virus from chronic hepatitis to hepatocellular carcinoma

14 December 2017

cites work

1 reference

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

21 January 2018

1 reference

7 January 2021

Vaccine development for hepatitis C.

1 reference

7 January 2021

Analysis of a successful immune response against hepatitis C virus

1 reference

7 January 2021

Control of heterologous hepatitis C virus infection in chimpanzees is associated with the quality of vaccine-induced peripheral T-helper immune response

1 reference

7 January 2021

Antibodies, viruses and vaccines

1 reference

7 January 2021

Vaccination of chimpanzees against infection by the hepatitis C virus

1 reference

7 January 2021

Vaccination of chimpanzees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV.

1 reference

7 January 2021

Optimal Induction of T-Cell Responses against Hepatitis C Virus E2 by Antigen Engineering in DNA Immunization

1 reference

7 January 2021

Hepatitis C virus core protein inhibits interleukin 12 and nitric oxide production from activated macrophages

1 reference

7 January 2021

Engineering N-glycosylation mutations in IL-12 enhances sustained cytotoxic T lymphocyte responses for DNA immunization.

1 reference

7 January 2021

Therapeutic effect of DNA vaccines combined with chemotherapy in a latent infection model after aerosol infection of mice with Mycobacterium tuberculosis

1 reference

7 January 2021

Rapid recruitment of macrophages in interleukin-12-mediated tumour regression

1 reference

7 January 2021

Efficient induction of T helper 1 CD4+ T-cell responses to hepatitis C virus core and E2 by a DNA prime-adenovirus boost.

1 reference

7 January 2021

Characterization of the immune response against hepatitis C infection in recovered, and chronically infected chimpanzees

1 reference

7 January 2021

Automation of nucleic acid extraction for NAT screening of individual blood units

1 reference

7 January 2021

Enhanced cellular immunity to hepatitis C virus nonstructural proteins by codelivery of granulocyte macrophage-colony stimulating factor gene in intramuscular DNA immunization

1 reference

7 January 2021

Protective immunity against heterologous challenge with encephalomyocarditis virus by VP1 DNA vaccination: effect of coinjection with a granulocyte-macrophage colony stimulating factor gene

1 reference

7 January 2021

Hepatitis C virus E2 protein purified from mammalian cells is frequently recognized by E2-specific antibodies in patient sera

1 reference

7 January 2021

Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes

1 reference

7 January 2021

In vitro assay for neutralizing antibody to hepatitis C virus: Evidence for broadly conserved neutralization epitopes

1 reference

7 January 2021

Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection

1 reference

7 January 2021

Previously Infected and Recovered Chimpanzees Exhibit Rapid Responses That Control Hepatitis C Virus Replication upon Rechallenge

1 reference

7 January 2021

The clearance of hepatitis C virus infection in chimpanzees may not necessarily correlate with the appearance of acquired immunity

1 reference

7 January 2021

Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know

1 reference

7 January 2021

Hepatitis C virus replication kinetics in chimpanzees with self-limited and chronic infections

1 reference

7 January 2021

Inhibition of Natural Killer Cells through Engagement of CD81 by the Major Hepatitis C Virus Envelope Protein

1 reference

7 January 2021

DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection

1 reference

7 January 2021

HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection

1 reference

7 January 2021

Impairment of natural killer (NK) cytotoxic activity in hepatitis C virus (HCV) infection

1 reference

7 January 2021

Decrease of CD56(+)T cells and natural killer cells in cirrhotic livers with hepatitis C may be involved in their susceptibility to hepatocellular carcinoma

1 reference

7 January 2021

Accumulation of natural killer and cytotoxic T large granular lymphocytes in the liver during virus infection

1 reference

7 January 2021

Screening blood donations for hepatitis C virus by polymerase chain reaction

1 reference

7 January 2021

Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.20934

1 reference

14 December 2017

1 reference